| 영문 | acid | 한글 | 산 |
|---|---|---|---|
| 설명 | 물에 녹았을 때 이온화하여 수소 이온을 만드는 물질. 신맛이 나고 청색 리트머스 종이를 붉게 변화시키며 염기와의 중화 반응에 의하여 물과 염을 만들고 이온화 열에서 수소보다 앞에 있는 금속과 반응하여 염을 만들면서 수소를 발생시킨다. 수소 원자를 이온화하는 힘의 강약에 따라 강산과 약산으로 나뉜다. |
||
| 영문 | acetic acid | 한글 | 아세트산, 초산 |
|---|---|---|---|
| 설명 | 분자식은 C2H4O2, 분자량 60.05의 저급 지방산이다. CH3COOH의 구조식을 가진 무색액체로 16.7℃에서 녹고 118.0℃에서 끓는다. 식초의 신맛을 내는 것이고, 농축된 것을 빙초산이라 한다. 상온에서는 액체이며 수용액은 약산성이다. 생체내에서는 일반적으로 아세틸 CoA로 존재하며 아세틸기의 공급원이 되는 외에 지방산이나 스테로이드 등의 생성재료로 중요하다. 아세틸 CoA로부터는 케톤체가 합성되며 조직의 에너지원이 된다. |
||
| 영문 | acetylsalicylic acid | 한글 | 아세틸살리실산 |
|---|---|---|---|
| 설명 | 상품명이 아스피린(asprin)인 약. 대표적인 비스테로이드 항염약이다. 즉 항염증(anti-inflammatory), 진통(analgesis), 해열(anti-pyretic)의 효과가 모두 뛰어나지만 위장장애, 과다호흡, 라이증후군(Reye syndrome) 등의 부작용이 있다. |
||
| 영문 | uric acid | 한글 | 요산 |
|---|---|---|---|
| 설명 | 결정성의 산. 2, 6, 8-trioxypurine. 화학식은 C5H4N4O3로 사람과 동물의 오줌에서 얻을 수 있다. 핵의 대사산물의 하나. 물, 알콜, 에테르(ether)에는 거의 녹지 않으나 알칼리염의 용액에는 녹는다. 이것의 나트륨염 형태(sodium urate)가 결석의 대부분을 차지한다. 급성백혈병 치료 초기단계와 통풍(Gout)에서 혈중요산이 급격히 오를 수 있다. |
||
| 영문 | acid-fast bacillus | 한글 | 항산막대균, 항산균 |
|---|---|---|---|
| 설명 | 아닐린 색소에 염색되기 힘드나 일단 염색되면 강산으로 처리하여도 탈색되지 아니하는 세균을 통틀어 이르는 말. 결해균, 나병균 따위가 있다. |
||
| AHA | acetohydroxamic acid; acquired hemolytic anemia; acute hemolytic anemia; American Heart Association;... |
|---|---|
| HA | H antigen; Hakim-Adams [syndrome]; halothane anesthesia; Hartley [guinea pig]; headache; health alli... |
| MA | malignant arrhythmia; management and administration; mandelic acid; masseter; Master of Arts; matern... |
| PCA | para-chloramphetamine; parietal cell antibody; passive cutaneous anaphylaxis; patient care assistant... |
| TA | alkaline tuberculin; arterial tension; axillary temperature; tactile afferent; Takayasu arteritis; t... |
| antibody affinity | A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes. (12 Dec 1998) |
|---|---|
| antibody aldolase | <enzyme> Prepared by reactive immuninization to catalyze a wide variety of aldol reactions and decarboxylations Registry number: EC 4.1.2.- Synonym: fab 33f12, aldolase catalytic antibody (26 Jun 1999) |
| antibody-coated bacteria test, urinary | Fluorescent antibody technique for visualizing antibody-bacteria complexes in urine. The presence or absence of antibody-coated bacteria in urine correlates with localization of urinary tract infection in the kidney or bladder, respectively. (12 Dec 1998) |
| antibody combining site | <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope). Also used of the site on a ligand molecule to which a cell surface receptor binds. (18 Nov 1997) |
| antibody deficiency disease | <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms. See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency. Synonym: antibody deficiency disease. (05 Mar 2000) |
| antibody deficiency syndrome | <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms. See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency. Synonym: antibody deficiency disease. (05 Mar 2000) |
| antibody-dependent cell cytotoxicity | The phenomenon of antibody-mediated target cell destruction by non-sensitised effector cells. The identity of the target cell varies, but it must possess surface IgG whose fc portion is intact. The effector cell is a "killer" cell possessing fc receptors. It may be a lymphocyte lacking conventional b- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. (12 Dec 1998) |
| antibody-dependent enhancement | Enhancement of viral infectivity caused by non-neutralizing antibodies. There are at least two mechanisms known to account for this: mediation by fc receptors (receptors, fc) or by complement receptors (receptors, complement). Either the virus is complexed with antiviral IgG and binds to fc receptors, or virus is coated with antiviral IgM and binds to complement receptors. (12 Dec 1998) |
| Antibody Directed Enzyme Prodrug Therapy | <pharmacology> A method for targeting a drug to a specific tissue, in which the targeting agent and the drug are administered separately. The drug is designed to be inactive (a prodrug) until it is converted by an enzyme, which is the targeting agent. The enzyme is coupled to an antibody that directs it to the tissue of interest. When the enzyme arrives at the tissue, the prodrug is activated only at that site, sparing other tissues from potentially toxic side effects. Acronym: ADEPT (14 Nov 1997) |
| antibody diversity | The phenomenon of immense variability characteristic of antibodies, which enables the immune system to react specifically against the essentially unlimited kinds of antigens it encounters. Antibody diversity is accounted for by three main theories: 1) the germ line theory, which holds that each antibody-producing cell has genes coding for all possible antibody specificities, but expresses only the one stimulated by antigen; 2) the somatic mutation theory, which holds that antibody-producing cells contain only a few genes, which produce antibody diversity by mutation; and 3) the gene rearrangement theory, which holds that antibody diversity is generated by the rearrangement of variable region gene segments during the differentiation of the antibody-producing cells. (12 Dec 1998) |
| antibody excess | In a precipitation test, the presence of antibody in an amount greater than that required to combine with all of the antigen present. (05 Mar 2000) |
| antibody-forming cell | <immunology> B-cells (plasma cells) that are dedicated to producing secreted antibodies. (09 Feb 1998) |
| antibody induced lysis | <haematology> The term is imprecise and should not be used since there is confusion as to which mechanism is involved, i.e. Natural killing or complement lysis. See: complement lysis, natural killer cells. (09 Feb 1998) |
| antibody producing cell | <immunology> A lymphocyte of the B series synthesising and releasing immunoglobulin. Equivalent to plasmacyte and plasma cell. (18 Nov 1997) |
| antibody-producing cells | Cells of the lymphoid series that can react with antigen to produce specific cell products called antibodies. Various cell subpopulations, often B-lymphocytes, can be defined, based on the different classes of immunoglobulins that they synthesise. (12 Dec 1998) |